Portfolio companies news

11 May 2015

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2015 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, today provided a business update and announced its financial results for the first quarter ended March 31, 2015.

05 May 2015

Transcend Medical Announces Intent to File Premarket Approval Application with FDA for the CyPass® Glaucoma Micro-Stent

Transcend Medical, Inc. announced today its intent to file a premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the CyPass Micro-Stent, a novel minimally invasive glaucoma surgical (MIGS) implant. The company recently completed the COMPASS pivotal trial evaluating the device, demonstrating sustained and consistent positive results through two years. Transcend Medical expects to file the PMA application with FDA in the second half of 2015.

04 May 2015

Clearside Biomedical, Inc. and Santen, Inc. Announce Research Collaboration in Glaucoma

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, and Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd., today announced the expansion of their research collaboration to include the field of glaucoma. 

04 May 2015

Tobira Therapeutics Completes Financing and Merger with Regado Biosciences

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, announced today the completion of its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, through May 4). In conjunction with the closing of the merger, Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing. 

02 May 2015

Atlas Genetics - Annual Summary 2014 - Setting the new standard in decentralised molecular diagnostics

Atlas Genetics Ltd., developer of innovative, ultra-rapid diagnostics to enable a ‘test and treat’ solution to infectious diseases, today announces its Annual Summary for 2014.

28 April 2015

Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye

Spark Therapeutics, Inc. (NASDAQ: ONCE) and Clearside Biomedical, Inc. announced today that they have entered into an option agreement under which Spark acquired exclusive rights to license Clearside's microinjector technology to deliver gene therapies to the back of the eye. Under the agreement, the companies will explore the feasibility of using Clearside's microinjector technology to deliver viral vectors to the choroid and the retina through the suprachoroidal space (SCS).

24 April 2015

Marinus Pharmaceuticals insider Gail M. Farfel Sells 30,000 Shares (MRNS)

Seth Barnet / WKRB News

Marinus Pharmaceuticals (NASDAQ:MRNS) insider Gail M. Farfel sold 30,000 shares of Marinus Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $9.48, for a total value of $284,400.00. 

24 April 2015

Hydrogel Corneal Inlay Promising in Pseudophakic Presbyopia

Laird Harrison / MedScape

A transparent hydrogel corneal inlay is a novel way to correct the vision of patients with pseudophakic presbyopia, a new study shows.

22 April 2015

Clearside Biomedical, Inc. Announces Purchase of iScience Patent Portfolio for Suprachoroidal Space Drug Delivery

Сlearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the purchase and acquisition of iScience Interventional Corporation’s patent portfolio covering drug delivery to the suprachoroidal space (SCS). 

20 April 2015

Breakthrough miraDry® Sweat Solution Appeals To Beauty Queen

One in five Americans is bothered by underarm sweating and embarrassed by the wetness and odor that comes with it.1 However, most are not aware that there is now a long-lasting solution that has been clinically proven to stop sweat in its tracks. The miraDry procedure is the only FDA-cleared device that delivers energy non-invasively to the underarm area, creating localized heat to permanently eliminate sweat glands with dramatic improvement seen in as little as one treatment.